Anzeige
Mehr »
Login
Sonntag, 11.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Kurseskalation am Montag? Diese Gamechanger-News macht es möglich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLX7 ISIN: US4884452065 Ticker-Symbol: 1GDA 
Tradegate
09.04.21
20:13 Uhr
7,700 Euro
-0,850
-9,94 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KEMPHARM INC Chart 1 Jahr
5-Tage-Chart
KEMPHARM INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,5507,80009.04.

Aktuelle News zur KEMPHARM Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrKemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M1
DoKemPharm enters amended licensing agreement for AZSTARYS-
KEMPHARM Aktie jetzt für 0€ handeln
DoKEMPHARM, INC - 8-K, Current Report1
DoKemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS2
23.03.KemPharm Stock Is Too Good to Be True After Its Recent Run-up9
16.03.KemPharm Is a Good Biotech Bet Even Without Potential Short Squeeze15
16.03.KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Squeeze11
12.03.KEMPHARM, INC - 10-K, Annual Report7
12.03.KemPharm, Inc. (KMPH) CEO Travis Mickle on Q4 2020 Results - Earnings Call Transcript7
12.03.KemPharm EPS misses by $0.40, beats on revenue4
11.03.KEMPHARM, INC - 8-K, Current Report1
11.03.KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results1
09.03.KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results5
08.03.Despite ADHD drug approval, KemPharm shares struggle, down 6.5%6
05.03.KemPharm: A Biotech Short Squeeze, Reality To Set In When Momentum Dies Out13
04.03.KemPharm to Present at the 33rd Annual Roth Conference5
04.03.KemPharm pares gains as H.C. Wainwright downgrades the stock to neutral8
04.03.KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent2.136NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping...
► Artikel lesen
03.03.KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys9
03.03.Mid-Day Market Update: Crude Oil Surges 3%; KemPharm Shares Spike Higher7
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1